An 83-year-old woman with mild hypertension and hypothyroidism was admitted to our hospital with acute pyelonephritis. She was treated with ampicillin plus sulbactam for 10 days with a good response while she was under rehabilitation receiving physical and speech therapy. However, she suddenly experienced fever, abdominal pain, and severe watery diarrhea. A stool sample was positive for *Clostridioides difficile* (*C. difficile*) antigen and toxins, and she was prescribed metronidazole 1,500 mg/day for 4 weeks for gastrointestinal symptoms due to *C. difficile* infection. Although the patient’s gastrointestinal symptoms improved, she later presented with an acute onset of dysphagia, nausea, vomiting, dizziness, and progressively altered mental status. Her vital signs were stable. Physical findings revealed no nuchal rigidity or meningeal irritation. However, neurologic examination showed dysarthria, minimal horizontal nystagmus, and unsteady gait. Results of laboratory testing were unremarkable.

Computed tomography showed moderate atrophy without cerebral bleeding. Magnetic resonance imaging (MRI) showed symmetrical T2-hyperintensity in the tectum of the midbrain, pontine tegmentum, and dentate nuclei indicating parenchymal vasogenic edema (Figure 1). Based on the characteristic imaging finding and the clinical history, we made a diagnosis of metronidazole-induced encephalopathy and immediately stopped the metronidazole therapy. After metronidazole was stopped, her neurologic symptoms improved gradually without remission.

**METRONIDAZOLE AND NEUROTOXICITY**

Metronidazole-induced encephalopathy is a relatively rare central nervous system disorder,
METRONIDAZOLE-INDUCED ENCEPHALOPATHY

associated with prolonged duration and high cumulative doses of metronidazole. Metronidazole is commonly used to treat a wide variety of infection-associated diseases, including pelvic inflammatory disease, bacterial vaginosis, intra-abdominal abscess, amebiasis, giardiasis, and *C difficile*. However, metronidazole has been reported to be inferior to vancomycin particularly for patients with severe cases of *C difficile* infection.

The mechanism of neurotoxicity due to metronidazole is unknown. It is thought that metabolites of metronidazole may bind to ribonucleic acid and interfere with ribonucleic acid protein synthesis, which can lead to axonal degeneration. Neurologic symptoms of metronidazole-induced encephalopathy vary widely among individual patients but can include cognitive deterioration, peripheral neuropathy, weakness, dizziness, vertigo, nausea, vomiting, headache, sensory loss, and seizures.

A characteristic MRI finding in patients with metronidazole-induced encephalopathy is bilateral involvement of the cerebellar dentate nuclei. However, this is also seen in other neurologic disorders such as Wernicke encephalopathy and isoniazid or methyl bromide toxicity. Thus, the definitive diagnosis should be based on a combination of the patient’s clinical history, laboratory findings, and imaging results. In most cases, the encephalopathy is reversible and generally improves within a few weeks after metronidazole is stopped. However, a delayed diagnosis can have progressive, irreversible consequences, including death. Clinicians should consider metronidazole-induced encephalopathy in a patient presenting with new psychiatric and neurologic symptoms and signs, especially in those with cerebellar symptoms who are taking metronidazole.

### DISCLOSURES

The authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

### REFERENCES


Address: Hiroki Matsuura, MD, Department of General Internal Medicine, Okayama City Hospital, 3-20-1, Omote-cho, Kitano-gase, Okayama-city, Okayama, 700-0962, Japan; superonewex0506@yahoo.co.jp